IMO 2125

Drug Profile

IMO 2125

Alternative Names: IMO-2125

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Lymphoma; Pancreatic cancer
  • Discontinued Hepatitis C

Most Recent Events

  • 29 Nov 2017 IMO 2125 receives Fast Track designation for Malignant melanoma [Intratumoural,Injection] (Combination therapy with ipilimumab, Second-line therapy or greater) in USA
  • 10 Sep 2017 Efficacy data from a phase I/II trial in Malingnant melanoma released by Idera Pharmaceuticals
  • 10 Sep 2017 Idera Pharmaceuticals plans a phase III trial for Malignant melanoma in March 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top